What Is in Force in Late 2026

Before building any process, a sponsor needs a clear picture of which rules apply today. Much of what circulates about EU clinical trial transparency was written in 2022 and 2023, when deferrals still existed and the transition deadline was still ahead. Both of those facts have changed, and several smaller updates in 2025 and 2026 matter for day-to-day work.

The Legal Base: Articles 37 and 81 of the Clinical Trials Regulation

Regulation (EU) No 536/2014, the Clinical Trials Regulation (CTR), has applied since January 31, 2022.4 Two of its articles drive almost everything in this article. Article 81 establishes the EU database, which is part of the Clinical Trials Information System (CTIS), and says it shall be publicly accessible unless confidentiality is justified on one of four grounds: protecting personal data, protecting commercially confidential information (CCI), protecting confidential communication between Member States during assessment, and ensuring effective supervision of the trial.3 Article 81(5) adds that nothing from an application dossier becomes public before a decision on the trial, and Article 81(7) says no personal data of trial participants shall be publicly accessible.3

Article 37 sets the reporting obligations at the end of a trial. Irrespective of the outcome, the sponsor must submit a summary of results (content set by Annex IV of the CTR) and a summary written for laypersons (content set by Annex V).6 Where trial results are used in a marketing authorization application, the applicant must also submit the clinical study report (CSR) within 30 days after the authorization is granted, the procedure is completed, or the application is withdrawn.3

Penalties are set by the Member States. EMA’s guidance notes that Article 94(2)(a) of the CTR refers to penalties for failing to submit information intended to be made public in the EU database.3 That makes publication a legal obligation with national enforcement behind it, not a courtesy.

The Revised CTIS Transparency Rules, in Force Since June 18, 2024

The EMA Management Board adopted revised CTIS transparency rules on October 5, 2023, after an eight-week public consultation in May and June 2023 that drew responses from 204 stakeholders.1 The revised rules have applied since June 18, 2024, when EMA also launched a new version of the CTIS public portal.9

The most important change was the removal of deferrals. Under the rules in place at CTIS launch, sponsors could ask to defer publication of certain data and documents, and for some trial types that allowed key documents, including the protocol, to stay unpublished for up to seven years after the end of the trial in the EU/EEA.1 The revised rules remove the deferral mechanism for every trial category. In its place, EMA publishes a smaller set of documents that matter most to patients and researchers, on fixed timelines set by trial category and population age, and sponsors protect CCI through redaction.1

Several principles did not change. The earliest point of publication is still the decision on the clinical trial application, positive or negative. Applications that are withdrawn, lapse, or are found not valid before a decision are not published. CTIS continues to feed the WHO International Clinical Trials Registry Platform. And the rules for trials authorized under the old Directive and held in EudraCT were left alone.1

The Transition From the Directive Ended in January 2025

The CTR replaced Directive 2001/20/EC, but it allowed a three-year transition. CTIS became the single entry point for new initial applications on January 31, 2023.4 Trials authorized under the Directive that were expected to continue after January 30, 2025 had to transition to the CTR, and from January 31, 2025 onward only the CTR applies. The Commission’s transition guidance states that trials not transitioned by that date are considered non-compliant and in breach of the CTR, with possible corrective measures, penalties, and liability.5

Two points from the transition still shape disclosure work. First, transitioned trials must meet CTR transparency requirements going forward, including the rules for summary results and the CSR.5 Second, trials that ended under the Directive and did not need to transition keep their results obligations in EudraCT, and the guidance says EudraCT remains open for result summaries after January 30, 2025.5 Many sponsors therefore still run two EU systems, not one.

What Changed in 2025 and 2026

The headline rules have been stable since mid-2024, but the operating detail has kept moving. These are the updates a disclosure team should have reflected in its procedures:

  • November 2025: EMA’s CCI and personal data guidance (version 2.1) changed the rules for non-substantial modifications on historical trials. A footnote in the current version explains that between June 18, 2024 and November 6, 2025, a Part I non-substantial modification on a historical trial did not trigger publication of Part I documents. After that date, it does.3
  • April 2026: Version 2.2 of the same guidance, dated April 30, 2026, points users to the Sponsor FAQs, which replace the earlier stand-alone Q&A on protecting CCI and personal data. The ACT EU quick guide on historical trials was updated the same day.2,3 Procedures that still cite the old Q&A should be updated.
  • Mid-2026: EMA set up a CTIS Task Force with the Heads of Medicines Agencies and the Commission. One stated aim is to identify the CTIS changes needed to support the proposed EU Biotech Act. EMA published its topics tracker on July 9, 2026.9 The CTIS Sponsor Handbook was reissued as version 6.4 on July 7, 2026.8
  • July 2026: The European Medicines Regulatory Network replied to Health Action International and other health groups about missing results in CTIS, setting out new monitoring and reminder measures (covered below).11
  • October 2026: The Commission published version 7.4 of the CTR Questions and Answers, endorsed by the Clinical Trials Coordination and Advisory Group, with a revised chapter on submitting the summary of results and the lay summary.17

The EU Biotech Act is a proposal, not law. The European Commission presented the Biotech Act on December 16, 2025. It would amend the CTR, with measures that include a stronger lead role for the reporting Member State, mandatory EU-harmonized templates, and a harmonized legal basis for processing personal data in trials. As of the Norwegian Medical Products Agency’s page update on October 28, 2026, the Biotech Act is still under negotiation.13 Nothing in it changes today’s publication rules. Sponsors should watch it, not build to it.

TopicStatus as of late October 2026Primary source
Revised CTIS transparency rulesApplicable since June 18, 2024EMA1,9
Deferral of publicationRemoved for trials submitted on or after June 18, 2024EMA1
Transition from the DirectiveEnded; only the CTR applies from January 31, 2025European Commission5
EudraCT results for non-transitioned Directive trialsStill required; EudraCT remains openEuropean Commission5
CTR Q&AVersion 7.4, October 2026, revised results chapterEuropean Commission17
EU Biotech ActProposed December 16, 2025; under negotiationNorwegian Medical Products Agency13

What CTIS Publishes, and When

The revised rules sort every trial into one of three categories, and the category, together with the age of the trial population, sets the publication clock. Getting the category right in the application form is therefore a disclosure decision as much as a regulatory one.

Three Trial Categories Drive the Clock

The categories carried over from the original disclosure rules, but they are no longer linked to deferrals.1

  • Category 1, pharmaceutical development trials: Phase 1 trials in healthy volunteers or patients, Phase 0 trials, bioequivalence and bioavailability trials, biosimilar similarity trials, and certain equivalence trials for combination or topical products.
  • Category 2, therapeutic exploratory and confirmatory trials: integrated Phase 1 and 2 trials, Phase 2 trials, integrated Phase 2 and 3 trials, and Phase 3 trials.
  • Category 3, therapeutic use trials: integrated Phase 3 and 4 trials, Phase 4 trials, and low-intervention trials.

The quick guide for users adds that only the most recent authorized application of a trial is made public, along with any initial application that was not authorized. Superseded versions of data and documents are no longer shown, although their decision dates remain visible.2,3

Structured Data Fields

Structured data are the fields sponsors fill in directly in CTIS: trial title, design, eligibility criteria, endpoints, product details, sites, sponsor contacts, and status dates. For Category 2 and 3 trials, and for Category 1 trials in children or under a pediatric investigation plan, these fields are published when the first Member State concerned issues its decision. For Category 1 trials in adults only, a limited set is published at decision (lay title, identifiers, therapeutic area and condition, population age and sex, sponsor details, and site details), and the rest waits until 30 months after the end of the trial in the EU/EEA.1,2

Dose and treatment-duration fields get extra protection in early development. For Category 1 trials and for integrated Phase 1 and 2 trials in Category 2, maximum daily dose, maximum total dose, and maximum treatment duration are published 30 months after the end of the trial in the EU/EEA.2

Status notifications (start of trial, start and end of recruitment, temporary halt, restart, end of trial, early termination) are published as soon as the sponsor submits them. Notifications of serious breaches, urgent safety measures, and unexpected events are published after the Member States assess them, or, for adult-only Category 1 trials, 30 months after the end of the trial and after assessment.1

Structured data cannot be redacted. EMA’s revised rules state plainly that “structured data fields cannot be redacted,” so users should not put personal data or CCI in them.1 A free-text field that names a manufacturing site, an unpublished biomarker, or a staff member’s personal email will be published as entered. Treat every structured field as public text from the moment you type it.

Documents

The revised rules cut the list of published documents to those most useful to patients and researchers. Everything not on the list stays in the secure domain.1,3

DocumentCategory 1, adults onlyCategory 1, pediatric or PIPCategories 2 and 3
Protocol, synopsis, patient-facing documents30 months after EU/EEA end of trialWhen results are submittedAt first Member State decision
SmPC (if available)NeverNeverAt first Member State decision
Subject information and informed consent form; recruitment arrangementsNeverNeverAt that Member State’s decision
Summary of results and lay summary30 months after EU/EEA end of trialAs soon as submittedAs soon as submitted
Clinical study report (when results support a marketing authorization)As soon as submittedAs soon as submittedAs soon as submitted
Investigator’s brochure, IMPD, assessment reports, RFIs and responses, inspection reportsNeverNeverNever

Source: EMA revised CTIS transparency rules, Annex I, and the ACT EU quick guide for users.1,2

For documents in scope, CTIS offers two slots: a version “for publication,” redacted as needed, and a version “not for publication” that holds the full text for Member State review. EMA’s guidance says the two versions should differ only by the redaction of personal data and CCI, and that when both are needed they should be uploaded together.3 According to the Sponsor Handbook, the “for publication” version of a results document is published overnight after submission for most trials.8 There is no review window in which a sponsor can catch a mistake after pressing submit.

Historical Trials Follow Their Own Rules

Trials submitted to CTIS before June 18, 2024 are called “historical” trials. For these, the structured data are published under the revised rules, but documents from applications submitted before that date are not published, whether or not the sponsor used deferrals.2,3 The date that counts is the submission date, not the date the draft was created.2

The catch is that new applications on a historical trial can trigger publication. A substantial modification (Part I or Part II), a Part I “change of sponsor” substantial modification, and, since November 6, 2025, a Part I non-substantial modification all trigger publication of the documents in scope of that application and of the revised rules. An application to add a Member State triggers publication of Part II documents only.3 CTIS looks at every document in scope of the application, not only the ones the sponsor changed.3 A protocol uploaded in 2023 in a “for publication” slot, never expecting to be published, can become public the day an unrelated amendment is decided. Sponsors with historical trials should review every “for publication” document on those trials before filing their next modification.

Results and Lay Summary Deadlines

The end-of-trial obligations are where most compliance failures happen, so the deadlines deserve precise treatment. All of the following comes from the Commission’s CTR Q&A and the EMA Sponsor Handbook.

The End of the Trial Starts the Clock

The CTR defines the end of a trial as the last visit of the last subject, or a later point defined in the protocol. The sponsor must notify each Member State concerned within 15 days of the end of the trial in that country, and again within 15 days of the end of the trial in the last Member State and the last third country.7 The results deadline runs from the end of the trial in all EU/EEA Member States concerned, not from the global end of the trial.7 This distinction matters for global programs in which the EU sites finish months before sites elsewhere.

One Year, or Six Months for Pediatric Trials

The summary of results and the lay summary must be submitted to CTIS within one year of the end of the trial in all Member States concerned, irrespective of the outcome.6 For pediatric trials, the summary of results is due within six months, based on a 2009 Commission communication. The Q&A describes narrow situations in which a pediatric trial may use the twelve-month limit instead, such as a trial outside the scope of Article 46(1) of Regulation (EC) No 1901/2006 where scientific reasons prevent meeting six months.6 The Sponsor Handbook applies the six-month deadline to trials in subjects aged 0 to 17 and to trials that are part of a pediatric investigation plan.8

Where scientific reasons make the deadline impossible (for example, the trial is still running in third countries and a statistical analysis would not be meaningful), Article 37(4) allows later submission, but only if the protocol explains why and says when results will come.7 The sponsor also records the anticipated date in CTIS when notifying the end of the trial.8 A delay that is not written into the protocol is simply a late submission.

Interim Results

Where the protocol provides for an intermediate data analysis, a summary of those results is due within one year of the analysis date, with no difference between adult and pediatric trials.6 The Q&A lists exceptions, including analyses where the blind must be kept, such as those reviewed by an independent data monitoring committee, and protocols that define clear decision criteria for continuing the trial.6 Interim summaries are never made public under the revised rules, which is why the Q&A says their findings should also be included in the final summary of results.6

Early Termination and Trials With No EU Participants

The current Q&A chapter on results, revised in October 2026, spells out several edge cases that disclosure teams often debate.6

  • A trial that was authorized, enrolled EU/EEA participants, and then ended early still needs both summaries, even when the data are too thin for a sound statistical analysis. In that case the summaries should explain why, leave out primary endpoint data points, and state that a sound analysis was not possible.
  • A trial terminated early in the EU/EEA with no EU/EEA participants ever enrolled should still have a document uploaded in both the results and lay summary slots, stating that no EU/EEA subjects took part and that the analysis includes no EU/EEA data.
  • A trial that was authorized but never enrolled anyone in the EU/EEA and then expired after two years needs no results in CTIS.
  • Where only some Member States enrolled participants, both summaries should say so clearly.

Clinical Study Reports and Public Health Emergencies

When a trial supports a marketing authorization, the CSR is due in CTIS within 30 days of the authorization decision, completion of the procedure, or withdrawal of the application, and it is published when submitted.2,7 EMA expects only minimal CCI redaction in a CSR and asks that the same level of redaction used for the CSR published under EMA Policy 0070 be applied to the CSR in CTIS.3 For trials with the potential to address a public health emergency, Article 17 of Regulation (EU) 2022/123 requires the protocol to be published after the decision and the summary of results to be submitted within a shorter timeline set by EMA.6

12 monthsSummary of results and lay summary deadline from the end of the trial in all EU/EEA Member States6
6 monthsSummary of results deadline for pediatric trials, per the CTR Q&A and Sponsor Handbook6,8
30 daysCSR deadline after a marketing authorization decision, completion, or withdrawal7

Why Compliance Is Harder Than the Rules Suggest

The deadlines are clear, yet the evidence so far shows that many sponsors miss them. Understanding why helps decide where to put effort.

What the First CTIS Compliance Study Found

In April 2026, a group of researchers posted a cross-sectional study of the 7,547 Phase 2 to 4 drug trials registered in CTIS up to November 2025, combining registry data with a manual review of results documents. The study is a preprint on medRxiv and has not been peer reviewed.12 Registration data were largely complete. Results reporting was not. Of 234 trials legally required to report results, 49.6% fully reported within the required timeframe, 20 trials (8.5%) fully reported late, and 98 trials (41.9%) had not fully reported. Compliance was similar for adult trials (79 of 158) and pediatric trials (37 of 76).12

234CTIS trials legally required to report results in the study cohort12
49.6%Fully reported results within the required timeframe12
41.9%Had not fully reported results (98 trials)12

“Fully reported” is the key phrase. The authors counted a trial as fully reported only when its scientific results document stated the number of enrolled participants and gave outcomes for all primary outcome measures, and a lay summary was also present.12 Of the 98 trials that fell short, 47 had no scientific results document at all, 47 had a document that lacked primary endpoint data (for example, results described as still being analyzed, vague narrative descriptions, or redacted outcome data), and 4 had scientific results but no lay summary.12 That points to a process problem as much as a timing problem: a submission can arrive on time and still fail Article 37.

How Regulators Are Responding

On June 15, 2026, Health Action International and other health groups wrote to EMA’s Management Board about missing results in CTIS. The joint reply from the European Medicines Regulatory Network, dated July 2, 2026, describes monitoring and quality of results as a shared responsibility of the Member States, the Commission, and EMA, and lists the measures under way:11

  • CTIS reminders to sponsors about results obligations, now supplemented by direct email notifications to CTIS users
  • enhanced monitoring that lets the network track timely submission and publication of results by Member State
  • revised training material, including chapter 5 of the Sponsor Handbook on submitting results
  • by the end of 2026, the number of trials with available summaries of results added to the quarterly ACT EU reports on the EU clinical trials environment
  • a communication campaign in the ACT EU 2026–2027 workplan focused on timely results submission
  • further measures being considered by Member States at national level

The practical message for sponsors is that missed results will become more visible, both to national authorities and to the public. A late lay summary that went unnoticed in 2024 is more likely to show up in a Member State report in 2027.

The United States Is Pushing at the Same Time

Sponsors running global programs face a parallel push in the United States. On April 13, 2026, FDA announced that on March 30 it had sent messages to more than 2,200 companies and researchers, linked to more than 3,000 registered trials, that did not appear to have submitted required results to ClinicalTrials.gov or may not have completed the National Library of Medicine’s quality control review. FDA said its internal analysis found that 29.6% of studies highly likely to fall under mandatory reporting have no results information submitted.14 The messages seek voluntary compliance, and FDA noted it may also send Pre-Notices and Notices of Noncompliance.14

FDA’s public list of Notices of Noncompliance shows ten notices, two of them dated October 7, 2026. If a responsible party does not take adequate corrective action within 30 calendar days of a notice, FDA can pursue enforcement, including civil money penalties.15 For a sponsor with the same trial registered in CTIS and on ClinicalTrials.gov, the two regimes now create pressure from both sides at once.

Where failures usually come from. Missed or incomplete disclosures rarely stem from someone deciding not to publish. They come from gaps between functions: the end-of-trial date known to clinical operations but not to the disclosure team, a lay summary that waits for the CSR, a redaction review that starts after the document is final, or a registry record that no one owns after the study team disbands. Each of the four systems below closes one of those gaps.

System One: A Disclosure Calendar Driven by Trial Events

Under the revised rules, every publication and submission deadline hangs off an event: a Member State decision, a status notification, the end of the trial in the EU/EEA, an interim analysis, or a marketing authorization decision. A spreadsheet of fixed dates goes stale the first time a site closes early. The calendar has to be driven by the events themselves.

Capture the Trigger Events at the Source

Most of the events that matter already live in the sponsor’s systems. Member State decisions arrive through CTIS. Site activation, last subject visit, and early closure are recorded in the clinical trial management system (CTMS). Interim analysis dates come from biostatistics. The marketing authorization decision is tracked by regulatory affairs. The disclosure calendar should read these events from their owning systems rather than relying on someone remembering to email the disclosure team.

EMA’s Sponsor Handbook is explicit about what CTIS is not. It says CTIS “is not a clinical trial management system,” and that sponsors “must use their own systems for storing trial-related data for compliance purposes.”8 Sponsors cannot treat the CTIS workspace as their tracking tool. They need their own record of what was submitted, when, and what the system will publish next.

Compute the Clock From Category and Population

Once the events are captured, the calendar applies the rules. For each trial, store the CTIS category, whether the population includes anyone under 18, whether the trial is part of a pediatric investigation plan, and whether it is an integrated Phase 1 and 2 design. Those four facts determine every publication date in the tables above. The calendar can then show, for each trial, what becomes public at the next decision, what becomes public 30 months after the EU/EEA end of trial, and when results are due.

1

Classify at Application

Confirm the CTIS category, population age, PIP status, and integrated-phase status in the application form, and record them in the disclosure system. These four fields drive every downstream date.

2

Flag Publication Events Before Decisions

For every pending application, list the documents that will become public at decision and confirm their “for publication” versions have passed redaction review. For historical trials, include every in-scope document, not only those being changed.

3

Track End of Trial by Country

Record the end of trial in each Member State, the end in the last Member State, and the global end. Set notification tasks at 15 days and results tasks at 12 months (6 for pediatric trials) from the end in all Member States.

4

Back-Schedule the Work

Work backward from each results deadline to set dates for database lock, results summary drafting, lay summary drafting, translation, review, and redaction. A deadline without upstream milestones is a deadline that will be missed.

5

Record Planned Delays in the Protocol

If results cannot be ready in time for scientific reasons, write the justification and expected date into the protocol and enter the anticipated results date in CTIS at the end-of-trial notification.

Put US Triggers on the Same Calendar

ClinicalTrials.gov uses different trigger events. Under 42 CFR Part 11, registration is due no later than 21 calendar days after the first participant is enrolled, and results are due no later than one year after the primary completion date, with a delayed-submission certification available in defined cases that is capped at two years after the certification.16 Records must be updated at least every 12 months, and certain elements, such as overall recruitment status, within 30 calendar days of a change.16 The primary completion date and the EU end of trial are often months apart. One calendar showing both clocks for the same trial prevents a team from treating the earlier deadline as the only one.

TriggerCTIS (EU CTR)ClinicalTrials.gov (42 CFR Part 11)
Registration or first publicationAt the first Member State decision on the applicationWithin 21 days after first participant enrolled
Status changesNotifications published as soon as submitted; end of trial notified within 15 daysRecruitment status updated within 30 days of a change
Results clock startsEnd of trial in all EU/EEA Member States concernedPrimary completion date
Standard results deadline12 months (6 months for pediatric trials)12 months
Lay summaryRequired with the summary of resultsNot required by the regulation
Planned delayJustified in the protocol, with a stated dateCertification in defined cases, capped at 2 years

Sources: CTR Q&A chapters 6 and 10, Sponsor Handbook, and 42 CFR Part 11.6,7,8,16

System Two: Redaction and Anonymization That Hold Up

With deferrals gone, redaction is the only tool a sponsor has to protect CCI in published documents, and anonymization is the only way to keep personal data out of them. EMA’s guidance makes the sponsor solely responsible for the quality of both, and it states that CTIS does not automatically verify whether personal data have been removed from the “for publication” version.3 That responsibility needs a process, not a last-minute review.

Two Different Problems

Personal Data

Staff, Investigators, and Authors

Redaction alone is acceptable for personal data of people other than participants. Signatures are never published, and author names must be removed from file metadata before upload. Principal investigator names and site details are published by design, and professional or functional contact details should be used.3

Personal Data

Trial Participants

Participant data, including pseudonymized IDs and indirect identifiers such as age, weight, height, or gender, must be anonymized in any published version. EMA expects sponsors to use the full range of anonymization techniques, assess re-identification risk, and take extra care with rare diseases, small populations, genetic data, and rare events.3

CCI

Information That May Qualify

Examples include manufacturer and supplier details, quantitative excipient composition, detailed synthesis and manufacturing processes, undisclosed development plans for other indications, unqualified biomarkers and novel methods, and, on justified grounds in the application dossier, dose details that are patentable matter.3

CCI

Information That Usually Does Not

Study identifiers, site names and principal investigators, countries and site counts, the sponsor’s name, names of CROs and other service providers (except in Category 1 trials), SOP numbers and titles, worldwide approval status, and anything already in the public domain or derived from textbooks and guidelines.3

Use the Two-Step Test and Write It Down

EMA’s guidance defines CCI as information that is not in the public domain and whose disclosure may undermine the legitimate economic interest or competitive position of the sponsor or another party. It suggests a two-step test: first rule out that the information is already public; then, with people who have the right scientific and technical expertise, decide whether disclosure would do harm.3 Redactions should be limited to the specific words, figures, or sentences that meet the test, not whole pages or tables, except for quality information where broader redaction is accepted.3

Two features of the guidance make a decision log essential. First, Member States may challenge the extent of redaction through a request for information, and sponsors should be able to show why each redaction is needed.3 Second, EMA expects consistency: redactions should be similar across a sponsor’s published documents for the same product, and the level of redaction should fall over time as development advances.3 A sponsor that redacts a biomarker name in one protocol and leaves it visible in another has weakened its own position. A log that records each redaction, the reason, the reviewer, and the date, and that can be searched by product, keeps decisions consistent and defensible.

The guidance also recommends that each sponsor keep a list of the places where information about its products is already public, at minimum its own websites, EMA’s website, trial registries such as CTIS, the EU Clinical Trials Register and ClinicalTrials.gov, other regulators’ websites, and the scientific literature.3 Checking that list is the first step of the two-step test, so it should be maintained, not rebuilt for each document.

Plan for Publication While Writing

The most efficient redaction is the one that is not needed. EMA’s guidance encourages medical writers to keep CCI out of documents where it is not required, to use templates that show what the regulations require, and to tag CCI at the time of writing so the redacted version is easier to prepare.3 A protocol that puts detailed manufacturing information in the body text, when the regulations only require it in the IMPD, creates redaction work that a better template would have avoided.

Timing also changes the redaction decision. For adult Category 1 trials, protocols are published 30 months after the end of the trial in the EU/EEA, so redaction at submission should cover only information that will still be CCI at that later date.3 A reviewer who redacts as if the document were going public tomorrow will over-redact, and EMA’s guidance warns that heavily redacted documents are of limited use to the public.1

Technical Controls

Redaction must be irreversible. EMA’s guidance calls for tools that apply a permanent overlay and make the redacted text unreadable and unsearchable.3 Sponsors should validate their redaction tool for that behavior, strip document metadata before upload, and keep a quality check that compares the “for publication” and “not for publication” versions to confirm the only differences are the intended redactions.

The wrong slot is a publication event. EMA’s guidance gives a specific example: if an investigator’s brochure is uploaded into the SmPC placeholder of a Category 2 or 3 trial, that brochure will be published unless the sponsor corrects it before the decision.3 EMA can remove corrupted or unlawfully processed information from the public domain on justified grounds, but its guidance says that should not be used as a routine way to fix sponsor errors.3 An upload checklist that confirms document type, placeholder, and version before submission is worth the few minutes it takes.

System Three: Lay Summary Production

The lay summary is the CTR’s most visible public output and the one sponsors most often leave until last. It has the same deadline as the technical summary, it must be written for people with no medical training, and for multinational trials it usually needs several translations. That combination makes it a production line, not a writing task.

What Annex V Requires

Annex V of the CTR sets out the elements a lay summary must address: trial identification, the sponsor’s name and contact details, general information about the trial, the population of subjects, the investigational medicinal products used, adverse reactions and their frequency, overall results, comments on the outcome, whether follow-up trials are foreseen, and where more information can be found.8,10 The Q&A adds that the lay summary should report at least the overall results, the primary endpoints, and patient-relevant secondary endpoints.6 A lay summary is required only for final results, not interim results.8

Language, Tone, and Readability

The Commission’s expert group recommendations on lay summaries remain the main practical reference. They ask sponsors to write for a general audience with no assumed knowledge, to keep the document as short as possible, to avoid copying from the technical summary, to follow health literacy and numeracy principles, and to make sure no promotional content is included.10 They suggest presenting numbers in a form such as “x out of xx people,” using language-specific readability tests, and, where feasible, testing the draft with patients or members of the public.10

On languages, the recommendations say that at a minimum the summary is expected in the local language of each EU country where the trial took place, matching the languages used in the patient information sheet in each country, with translated versions uploaded separately.10 They also ask that translations keep the original meaning and non-promotional tone, and take account of the cultural validity of medical terms.10 The technical summary of results, by contrast, is expected in English only, with no translations required.6

A Production Line That Meets the Deadline

A sponsor with a steady flow of trial completions needs lay summaries produced the same way every time. The elements below are the ones that most often decide whether a summary arrives on time.

Template

One Controlled Template

A template mapped to the Annex V elements, with standard plain-language text for recurring content (what a Phase 2 trial is, what blinding means), approved once and reused, keeps each summary from starting from a blank page.

Timing

Start From the Results Tables

The lay summary can be drafted as soon as topline results and adverse event tables are final. Waiting for the CSR, which often comes much later, is the most common reason the twelve-month deadline slips.

Review

Non-Promotional and Medical Review

Reviewers check that results are stated neutrally, that numbers match the technical summary, and that adverse reactions are not minimized. This review should be separate from marketing review.

Translation

Translation as a Tracked Workstream

Languages are known from the patient information sheets at authorization. Booking translation and linguistic review capacity in advance, with a glossary of approved lay terms per language, removes a predictable bottleneck.

The same redaction and anonymization rules apply to lay summaries. EMA’s guidance notes that the final summary of results is a document where preserving data utility while protecting participants is especially important, and where a quantitative assessment of re-identification risk may be preferred.3 In small or rare disease trials, a lay summary that reports one serious adverse event in a named country can identify a participant. The anonymization review must cover the lay summary, not only the technical one.

The expert group recommendations also note that the lay summary in the EU database should not be the only way results are communicated to participants, and that sponsors may share results with investigators to pass on to the people who took part.10 A sponsor that builds a good lay summary process can reuse it for that wider communication.

System Four: One Record Across CTIS, EudraCT, and ClinicalTrials.gov

A global sponsor may publish the same trial in CTIS, on ClinicalTrials.gov, and, for older programs, in EudraCT through the EU Clinical Trials Register. Each registry has its own fields, definitions, and update rules. EMA’s own CCI guidance lists these registries among the public sources a sponsor must check before calling information confidential.3 If the protocol title, endpoints, or enrollment numbers differ between them, a reader can see it, and so can a regulator.

Where the Registries Differ by Design

FeatureCTISEudraCT / EU Clinical Trials RegisterClinicalTrials.gov
ScopeTrials under the CTR, including transitioned trialsTrials under the Directive that did not transitionApplicable clinical trials under US law, plus voluntary registrations
Results triggerEnd of trial in all EU/EEA Member StatesExisting EudraCT obligations for Directive trialsPrimary completion date
Lay summaryRequiredNot part of the CTR lay summary requirementNot required
Who publishesEMA, on rule-based timelines after Member State decisionsEMANational Library of Medicine, after quality control review
Update rulesThrough notifications and modification applicationsResults submission remains openAt least every 12 months; key fields within 30 days

Sources: EMA revised rules, Commission transition guidance, CTR Q&A, FDA, and 42 CFR Part 11.1,5,7,14,16

Some differences cannot be removed, and they should be explained rather than hidden. An EU end-of-trial date and a US primary completion date for the same study are different data points, not a mistake. Enrollment in an EU summary may legitimately differ from global enrollment on ClinicalTrials.gov if the EU record is reported by Member State. The goal is not identical records. It is records whose differences can each be traced to a rule.

Build a Master Disclosure Record

The strongest approach is a single internal record for each trial that holds the disclosure-relevant data once and feeds each registry. At a minimum it holds the identifiers (EU trial number, EudraCT number where relevant, NCT number, and protocol code), titles in technical and lay form, design, eligibility, endpoints, key dates by country, the CTIS category and population flags, and the status of every disclosure obligation. Much of this already exists in the CTMS and the regulatory information management system. The disclosure record links to those sources rather than copying them by hand.

Identifiers deserve special care. EMA’s guidance says study identification numbers such as EudraCT and NCT numbers are unlikely ever to be CCI and should not be redacted.3 Cross-referencing them in each registry helps readers and the WHO registry platform link records for the same trial.

Product and organization data add another source of drift. The Sponsor Handbook explains that CTIS copies product data from the Extended EudraVigilance Medicinal Product Dictionary (XEVMPD) and organization data from the Organisation Management Service (OMS) at the time of retrieval, and does not update them automatically when those databases change.8 A sponsor that updates its organization record in OMS must also update each affected trial through the appropriate CTIS application. The master record should flag trials that still carry outdated product or sponsor details.

Reconcile on a Schedule

Even with a master record, registries drift. A quarterly reconciliation that compares each published record against the master, and records the reason for every difference, catches problems before an outside party does. Useful checks include:

  • titles, endpoints, and eligibility criteria that differ between CTIS and ClinicalTrials.gov without a documented reason
  • trials with an EU end-of-trial date but no results task, or a primary completion date with no ClinicalTrials.gov results due date
  • CTIS trials past their results deadline with only one of the two required summaries
  • Directive-era trials that ended before 2025 and still have outstanding EudraCT results
  • historical CTIS trials with “for publication” documents that have not been reviewed against current redaction standards
  • ClinicalTrials.gov records not updated in the last 12 months

What a working disclosure function looks like. Every trial has a named disclosure owner from authorization to final results. Trigger events flow in from the CTMS, CTIS, and regulatory systems. The calendar shows both EU and US clocks. Redaction decisions are logged by product and reviewed for consistency. Lay summaries are drafted from final results tables, not the CSR. A quarterly reconciliation report goes to clinical operations and quality leadership, with overdue items escalated. None of this needs a large team; it needs clear ownership and data that move without manual relays.

Who Owns Disclosure

Disclosure touches clinical operations, regulatory affairs, medical writing, biostatistics, data privacy, legal, and quality. In many organizations each function owns one piece and no one owns the whole. The EMA letter’s emphasis on Member State monitoring, and FDA’s renewed outreach, both point to the same need: one accountable owner who can see every trial’s status across every registry. For a smaller biotech, that may be a single person supported by a clear SOP and a well-built tracker. For a larger sponsor, it is usually a dedicated disclosure team with a system that pulls data from the CTMS and regulatory systems. In both cases the SOP should cite the current EMA guidance (version 2.2 of the CCI guidance, the Sponsor FAQs, and version 7.4 of the CTR Q&A) and should be reviewed whenever those documents change.3,17

Conclusion

EU CTR transparency has reached a stable point. The revised CTIS rules have applied for more than two years, deferrals are gone for new trials, and the Directive transition is complete. The open questions are no longer about what the rules say but about whether sponsors can meet them reliably: publish the right documents at each decision, redact consistently, deliver complete results and lay summaries on time, and keep three registries telling the same story. Early evidence suggests many cannot yet, and regulators on both sides of the Atlantic have started to look more closely. The Biotech Act may change parts of the CTR in time, but it does not change what is due today.

Sakara Digital works with pharma and biotech organizations on the systems and data behind clinical operations, including the processes that connect trial events to regulatory and public disclosure obligations. If you are reviewing how your organization tracks CTIS and ClinicalTrials.gov obligations, or planning a disclosure process that does not depend on manual handoffs, we are happy to have that conversation.

For Further Reading